Matthew Johnson, MD
Interventional Cardiology · Lincoln, NENPI 1578536488
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $145,430 of the $161,907 with a category attached, or 89.8%. Johnson & Johnson accounts for 96.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $107,813 and has fallen 99.6% since, to $476 in 2025. Among interventional cardiology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $462.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$155K
- Abbott$2K
- Medtronic$2K
- Abiomed$429
- Regeneron Healthcare Solutions, Inc.$275
- Edwards Lifesciences$218
- plus $1K from 22 others
Across 19 payments — averaging $3764.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Microvention, Inc.$29K
- Abbott$23K
- Bayer$19K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$145,43090%
- Travel & lodging$8,5605%
- Food & beverage$7,5955%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 137 | $155,362 |
| Abbott | 50 | $2,396 |
| Medtronic(2 entities) | 94 | $2,200 |
| Abiomed | 6 | $429 |
| Regeneron Healthcare Solutions, Inc. | 9 | $275 |
| Edwards Lifesciences | 8 | $218 |
| Cardiovascular Systems Inc. | 3 | $143 |
| Impulse Dynamics (USA) Inc. | 3 | $137 |
| Philips North America LLC | 2 | $103 |
| AstraZeneca | 5 | $72 |
| Surmodics, Inc. | 3 | $66 |
| Pfizer | 3 | $60 |
| Itamar Medical Inc | 1 | $51 |
| EKOS Corporation | 1 | $47 |
| Chiesi USA, Inc. | 2 | $46 |
| Merck | 3 | $43 |
| Biosense Webster, Inc. | 1 | $38 |
| Novartis | 2 | $32 |
| Amgen | 1 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $24 |
| Penumbra, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $19 |
| Shockwave Medical, Inc | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Stryker | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$153,022
- CoreValve Evolut$244
- Impella$144
- PRALUENT$122
- Optis Coronary Imaging System$110
- AMPLATZER Occluders$109
How this compares
$161,907 in reported general payments places this provider in the 95th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 380 | $274,848 |
| EliquisApixaban | 205 | $188,965 |
| XareltoRivaroxaban | 210 | $188,495 |
| EntrestoSacubitril/Valsartan | 137 | $139,538 |
| Praluent PenAlirocumab | 162 | $93,543 |
| BrilintaTicagrelor | 32 | $23,629 |
| MultaqDronedarone Hcl | 12 | $22,050 |
| JardianceEmpagliflozin | 13 | $14,001 |
| Nebivolol Hcl | 162 | $5,904 |
| Metoprolol Succinate | 408 | $4,775 |
| Ranolazine ErRanolazine | 50 | $4,098 |
| BystolicNebivolol Hcl | 21 | $4,044 |
| Atorvastatin Calcium | 467 | $3,853 |
| ClopidogrelClopidogrel Bisulfate | 253 | $2,187 |
| Potassium Chloride | 126 | $2,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60 | $188,965205 claims |
| Johnson & JohnsonXarelto | $155,362 | $188,495210 claims |
| NovartisEntresto | $32 | $139,538137 claims |
| AstraZenecaBrilinta | $72 | $23,62932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Lincoln
- Brock CookmanLincoln$782K
- Steven MartinLincoln$55K
- Natraj KattaLincoln$18K
- Hemantha KoduriLincoln$10K
- Denes KorpasLincoln$9K
- Harpaul BajwaLincoln$7K
- Zachary SingsankLincoln$4K
- Douglas NetzLincoln$3K
- Vishwajeth BhoopalamLincoln$3K
- Melissa AlvarezLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.